Money
Filter News
Found 84,557 articles
-
Continuing 2024’s biotech initial public offering rally, Boundless Bio will debut Thursday on the Nasdaq with the proceeds used to advance its pipeline of extrachromosomal DNA cancer assets.
-
Stoke Therapeutics plans to offer up more than 5.5 million shares of its common stock following positive Phase I/IIa data for its Dravet syndrome candidate.
-
Follow along as BioSpace keeps you up to date on the latest pharma and biotech M&As, from announcements to closings.
-
Ocean Biomedical (NASDAQ: OCEA) Congratulates JV Partner, Virion Therapeutics, on Promising First-Ever Human Phase 1B Clinical Safety Data for Their Lead Checkpoint Modifier-Containing Immunotherapy for HBV Functional Cure, at Global APASL
3/28/2024
Ocean Biomedical, Inc. congratulates its JV partner Virion Therapeutics, LLC, a clinical-stage biotechnology company developing novel T cell-based immunotherapies, on its late breaker oral presentation highlighting the first-ever human data from its novel checkpoint modifier immunotherapy for HBV functional cure, at the 33rd Annual Meeting of APASL, taking place in Kyoto, Japan from March 27 - 31.
-
Can-Fite Reports 2023 Financial Results and Clinical Update
3/28/2024
Can-Fite BioPharma Ltd. announced financial results and clinical updates for the twelve months ended December 31, 2023.
-
NRx Pharmaceuticals Announces Reverse Stock Split to Maintain Nasdaq Listing
3/28/2024
NRx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, announced that it intends to effect a reverse stock split of its common stock at a ratio of 1 post-split share for every 10 pre-split shares.
-
CASI Pharmaceuticals Announces Fourth Quarter and Full-Year 2023 Business and Financial Results
3/28/2024
CASI Pharmaceuticals, Inc. reported business and financial results for the year ended December 31, 2023, and provided an update on key highlights for 2023.
-
Tevogen Bio Reports Series A-1 Preferred Stock Investment at $10 Conversion Price
3/28/2024
Tevogen Bio Holdings has entered into a securities purchase agreement with an existing investor pursuant to which the investor agreed to purchase shares of newly designated Series A-1 Preferred Stock of the Company in lieu of Series A Preferred Stock that the investor earlier agreed to purchase, for an aggregate purchase price of $6.0 million.
-
Galera Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Corporate Updates
3/28/2024
Galera Therapeutics, Inc. announced financial results for the fourth quarter and year ended December 31, 2023 and provided recent corporate updates.
-
Vivos Therapeutics Schedules Release of Fourth Quarter and Full Year 2023 Financial Results and Conference Call
3/28/2024
Vivos Therapeutics, Inc. announced it plans to release its fourth quarter and full year 2023 financial results after market close today, Thursday, March 28, 2024.
-
Seres Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - March 28, 2024
3/28/2024
Seres Therapeutics, Inc. announced that on March 25, 2024, the Compensation and Talent Committee of Seres’ board of directors granted inducement equity grants covering an aggregate of 700,000 shares of its common stock to Marella Thorell, the Company’s new Executive Vice President and Chief Financial Officer, consisting entirely of stock options.
-
Integer Schedules First Quarter 2024 Earnings Release and Conference Call for April 25, 2024
3/28/2024
Integer Holdings Corporation announced that it plans to release financial and operational results for first quarter 2024, at 7 a.m. Central Time / 8 a.m. Eastern Time on Thursday, April 25, 2024.
-
IMUNON Reports 2023 Financial Results and Provides Business Update
3/28/2024
IMUNON, Inc. reported financial results for the year ended December 31, 2023.
-
Xilio Therapeutics Announces $11.3 Million Private Placement Equity Financing
3/28/2024
Xilio Therapeutics, Inc. announced that it has entered into a securities purchase agreement with certain existing accredited investors, including Bain Capital Life Sciences and Rock Springs Capital.
-
Monopar Reports Fourth Quarter and Full-Year 2023 Financial Results and Recent Developments
3/28/2024
Monopar Therapeutics Inc. announced fourth quarter and full-year 2023 financial results and summarized recent developments.
-
Canadian MedTech Startup Amplifies Fight Against Tuberculosis with New Grant
3/28/2024
Canadian-based Noze, a global leader in the breath-based diagnostic space, announced it received a new grant from the Bill & Melinda Gates Foundation, bringing the foundation's total grant funding to Noze to $1.8 million.
-
Tonix Pharmaceuticals Announces Pricing of $4.4 Million Registered Direct Offering
3/28/2024
Tonix Pharmaceuticals Holding Corp. announced it has entered into a securities purchase agreement with existing healthcare focused institutional investors of the Company for the purchase and sale of 14,666,666 shares of its common stock and warrants to purchase up to an aggregate of 14,666,666 shares of common stock in a registered direct offering at a combined offering price of $0.30 per share and accompanying warrant.
-
CervoMed Announces Up to $149.4 Million Private Placement Financing Joined by Leading Healthcare Investors
3/28/2024
CervoMed Inc. announced that it has entered into a definitive securities purchase agreement for a private placement to sell an aggregate of 2,532,285 units, each Unit comprised of one share of its common stock or one pre-funded warrant to purchase shares of its common stock, and in each case, one Series A warrant to purchase shares of its common stock to a select group of institutional and accredited healthcare specialist investors in a private placement.
-
Psychemedics Corporation Reports 2023 Financial Results
3/28/2024
Psychemedics Corporation, the world’s leading provider of hair testing for drugs of abuse, announced financial results for the year ended December 31, 2023.
-
Amneal to Ring the Nasdaq Closing Bell on April 2, 2024
3/28/2024
Amneal Pharmaceuticals, Inc., a global pharmaceutical company, announced that Chirag and Chintu Patel, Co-founders and Co-Chief Executive Officers, will ring the Nasdaq closing bell on Tuesday, April 2, 2024.